https://uk.marketscreener.com/quote/stock/ONO-PHARMACEUTICAL-CO-LTD-6492021/
Ono Pharmaceutical Co., Ltd. Share Price (4528) - Stock Japan Exchange - MarketScreener UK
Ono Pharmaceutical Co., Ltd. (4528:TYO): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Ono Pharmaceutical Co., Ltd. | Japan...
ono pharmaceuticalshare pricecoltdstock
https://pharmadevicenews.com/ono-pharmaceutical-strengthens-early-stage-pipeline-with-congruence-platform-deal/
Ono Pharmaceutical strengthens early-stage pipeline with Congruence platform deal - PharmaDeviceNews
Mar 3, 2026 - Ono Pharmaceutical expands its Congruence alliance into neurology and immunology. Explore what this means for AI-driven drug discovery and pipeline risk.
ono pharmaceuticalearly stagepipelinecongruenceplatform
https://adisinsight.springer.com/drugs/800031070?error=cookies_not_supported&code=fda4a59a-3801-4163-8fa5-ab172d792f9c
Research programme: ion channel targeted therapeutics - Evotec SE/Ono Pharmaceutical - AdisInsight
Evotec SE (formerly Evotec AG) and Ono Pharmaceutical are developing orally available small molecule candidates against an undisclosed ion channel. This
research programmeion channeltargeted therapeuticsono pharmaceuticalevotec
https://www.pharmacompass.com/radio-compass-news/ono-pharmaceutical
Ono pharmaceutical | Radio Compass News | PharmaCompass.com
Read the Latest News: Ono pharmaceutical aggregated by PharmaCompass.com.
ono pharmaceuticalcompass newsradio
https://www.asiaone.com/business-wires/numab-therapeutics-and-ono-pharmaceutical-announce-option-and-collaboration-agreement
Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop...
Feb 14, 2024 - Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer...
ono pharmaceuticalan optioncollaboration agreementtherapeuticsannounce
https://www.biopharmaapac.com/news/33/6910/ono-pharmaceutical-wins-eu-approval-for-vimseltinib-as-first-tgct-therapy.html
Ono Pharmaceutical Wins EU Approval for Vimseltinib as First TGCT Therapy
Ono Pharmaceutical Wins EU Approval for Vimseltinib as First TGCT Therapy
ono pharmaceuticalwinsapprovalvimseltinibfirst
https://synapse.net/medicine/870/
ONOACT for I.V. Infusion 50mg : Ono Pharmaceutical Co., Ltd.| synapse
Information on ONOACT for I.V. Infusion 50mg from Ono Pharmaceutical Co., Ltd. online, Ministry of Health and Welfare Code is 2123404D1033, packaging is 1 vial...
ono pharmaceuticalvinfusioncoltd
https://www.macrotrends.net/stocks/charts/OPHLF/ono-pharmaceutical/eps-earnings-per-share-diluted
Ono Pharmaceutical EPS - Earnings per Share 2012-2025 | OPHLF | MacroTrends
Ono Pharmaceutical annual and quarterly earnings per share history from 2012 to 2025. Earnings per share can be defined as a company's net earnings or losses...
earnings per shareono pharmaceuticalepsmacrotrends
https://pressreleasejapan.net/tag/ono-pharmaceutical-co/
Ono Pharmaceutical Co Archives - PressReleaseJapan.net
ono pharmaceuticalcoarchives